查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854828

PARP抑制劑治療市場按適應症、藥物、治療線、治療環境、最終用戶、分銷管道、治療類型和患者年齡層分類－2025-2032年全球預測

PARP Inhibitors Drug Therapy Market by Indication, Drug, Line Of Therapy, Treatment Setting, End User, Distribution Channel, Therapy Type, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，PARP 抑制劑藥物市場將成長至 151.1 億美元，複合年成長率為 9.47%。

關鍵市場統計數據
基準年 2024 73.2億美元
預計年份：2025年 80.1億美元
預測年份 2032 151.1億美元
複合年成長率 (%) 9.47%

全面介紹PARP抑制劑療法，重點在於闡述臨床證據、監管里程碑以及影響其在癌症治療中應用的給藥途徑。

隨著標靶治療在腫瘤學領域的不斷發展，PARP抑制劑已成為精準醫療的前沿藥物，其適應症不斷擴大，臨床應用也日益成熟。本書概述了PARP抑制劑的治療原理、目前PARP抑制劑有望發揮最大作用的臨床領域，以及影響其應用推廣的相關人員群體。本書著重闡述PARP抑制劑的治療背景，而非量化市場規模，而是著重於其作用機制、監管里程碑以及影響決策的臨床終點。

PARP抑制劑利用腫瘤特異性的DNA損傷修復路徑漏洞，賦予依賴同源重組缺陷的癌症合成致死性。 PARP抑制劑的臨床效用涵蓋多種具有不同生物標記譜和疾病階段的固體癌。從最初的單藥治療到現代的聯合治療治療和維持治療，PARP抑制劑已在特定患者群體中展現出持久的療效，使其成為多線治療中可行的選擇。本導言重點介紹這些臨床曲折點，並幫助讀者了解適應症、生物標記狀態和治療背景如何影響藥物的研發和商業化。

同時，醫療服務模式的轉變——從門診腫瘤輸液的擴展到透過專科藥房進行分銷的轉變——正在重塑PARP抑制劑的適用範圍。支付方的期望和對真實世界證據的重視日益體現在治療流程中，而臨床醫生的實踐模式也在不斷調整以適應不斷變化的指南建議。本節將深入探討這些變革性的變化、細分市場的細微差別、監管和報銷機制，以及為相關人員在應對PARP抑制劑在整個治療領域複雜應用過程中提出的實用建議。

對影響PARP抑制劑臨床開發策略、監管路徑和進入模式的關鍵變革性轉變進行深入分析

在生物標記科學的進步、聯合治療的開發以及監管環境的不斷演變等因素的推動下，PARP抑制劑的治療格局正在發生顯著變化。生物標記的完善，特別是圍繞BRCA突變和廣泛的同源重組缺陷特徵的生物標記，不僅拓展了其臨床應用的合理性，也提高了患者選擇的精準度。基因組分析正被整合到臨床決策的早期階段，使臨床醫生能夠識別PARP定向治療的候選患者並選擇治療方法，主要包括分子標靶藥物和免疫腫瘤藥物。

同時，治療模式正從單一藥物維持治療策略轉向更複雜的組合方案，將PARP抑制劑與抗血管新生藥物、免疫查核點抑制劑或細胞毒性藥物合併使用。這些聯合治療旨在擴大有效患者群體並增強療效，但也帶來了安全性管理、劑量最佳化和醫療照護支付談判的新考量。監管路徑也在適應這些發展，包括與生物標記定義的患者群體相關的適應症擴展，以及需要強力的驗證性證據的加速核准。這些監管動態也影響臨床試驗設計和商業化規劃。

醫療服務模式也正在發生類似的變化。門診和專科診所的興起，以及零售和線上藥局銷售管道的不斷拓展，都對病患的就醫便利性和用藥依從性產生了影響。隨著相關人員尋求檢驗長期療效、比較療效和價值提案，真實世界證據計畫和核准後研究的重要性日益凸顯。總而言之，這些轉變正在重塑臨床路徑和商業策略，需要敏捷的跨職能團隊協調臨床開發、監管溝通和支付方溝通，以最大限度地發揮治療效果。

本文探討了美國累積關稅（有效期至2025年）如何影響藥品供應鏈中的商業策略，包括進入問題和支付方參與情況。

美國對藥品加徵的累積關稅將持續到2025年，這給醫藥供應鏈帶來了許多成本壓力，影響了採購、定價策略和相關人員的談判。這些關稅措施影響了原料藥的採購、成品進口和輔助醫療產品，迫使許多生產商和經銷商實現供應商多元化、管理庫存並重新評估與全球合作夥伴的合約條款。製造地集中在美國境外的公司尤其面臨調整物流和減少成本轉嫁給支付方和醫療服務提供者的壓力。

為此，許多相關人員優先考慮供應鏈的韌性，包括尋找替代製造地、將關鍵零件近岸外包以及重新談判供應商契約，以確保更長期的價格穩定性。支付方和綜合醫療服務網路加強了對單位成本和治療成本合理性的審查，加快了基於價值的合約模式和基於結果的報銷試點項目的實施。在醫療服務提供方層面，醫療機構重新評估了處方發放和化療路徑通訊協定，以在預算限制下維持醫療服務的連續性。

在臨床上，關稅主導的環境凸顯了證明PARP抑制劑之間價值差異的重要性，尤其是在討論治療互換性時。真實世界證據的收集和藥物經濟學模型已成為支付方討論的核心，影響著醫保覆蓋範圍和預先核准流程。這些調整凸顯了宏觀經濟和貿易政策如何對創新應用產生下游壓力，因此需要積極主動的供應鏈策略、嚴格的價值論證以及與支付方和醫療服務提供者的協作，以確保患者在外部成本波動期間能夠獲得治療。

生物標記物譜涵蓋適應症、藥物特性、治療方案，並提供詳細的細分洞察，將治療環境和分銷管道與臨床和商業策略聯繫起來。

從適應症層面的分類入手，進行穩健的患者群體分類對於理解PARP抑制劑作用的異質性患者群體和臨床背景至關重要。在乳癌中，依受體類型進行分層可區分荷爾蒙受體陽性和三陰性乳癌，二者有不同的反應模式和治療順序。在卵巢癌中，BRCA突變、同源重組缺陷陽性和非HRD患者群體對PARP定向治療的敏感性存在差異，因此需要密切注意生物標記狀態。在胰臟癌中，按疾病分期進行分類可區分晚期患者和早期患者，從而影響維持治療策略的可行性和臨床試驗的合格。在攝護腺癌中，分期區分同樣可區分轉移性和非轉移性疾病，進而改變治療終點、存活預期以及與雄性激素受體標靶治療的整合。

尼拉帕尼、奧拉帕尼、盧卡帕尼和他拉唑帕尼這四種藥物的藥物層面差異，決定了其臨床定位，而這種定位基於藥理學特性、給藥方案、安全性訊號以及核准或臨床實驗的適應症。一線、維持和後續治療的分類影響著治療目標，例如誘導緩解、延長疾病進展時間或抗藥性後的挽救治療。治療環境是另一個重要因素。住院與門診病人環境會影響給藥流程、監測資源、輸液中心的角色以及門診腫瘤科的口服藥物管理。

包括醫院、零售藥局和專科診所在內的終端用戶與包括醫院藥局、線上藥局和零售藥局網路在內的分銷管道互動，從而形成多樣化的用藥途徑和依從性接觸點。治療方法類型可分為聯合治療治療和單藥治療，這會影響安全性管理和與支付者的談判。此外，根據患者年齡將患者分為成人和老年患者，這會帶來併發症負擔、多重用藥風險和實際耐受性的差異，這些差異必須體現在臨床方案和患者援助計畫中。整合這種年齡分類有助於更精準地分類臨床試驗隊列，向支付方清晰地闡述價值，並建立客製化的患者援助模式，從而提高依從性和治療效果。

主要亮點在於揭示了美洲、歐洲、中東和非洲以及亞太地區在PARP抑制劑監管診斷和支付方優先事項方面的差異如何影響PARP抑制劑的普及應用。

PARP抑制劑的研發、核准和應用將取決於區域動態，包括不同的臨床實踐、監管預期和支付方情況。在美洲，監管機構和支付方優先考慮療效比較和真實世界表現，而臨床應用則受到已建立的基因組檢測途徑和高普及率的綜合專科藥房服務的影響。這些因素共同創造了一種環境，在這種環境下，差異化的臨床證據和以支付方為中心的價值證明對治療可及性具有尤為重要的影響。

歐洲、中東和非洲地區法律規範和報銷體系的差異，要求在區域證據生成和衛生技術評估方面採取細緻的策略。基因組檢測基礎設施和資源分配的差異意味著，即使在相鄰市場，其普及率也可能存在顯著差異，因此需要製定量身定做的准入策略，以反映各國的衛生優先事項、與當地臨床實驗夥伴關係以及採用適應性定價方法。相較之下，亞太地區既有正在快速現代化和擴展基因組診斷能力的市場，也有基礎設施限制了普及速度的地區。這種多樣性要求制定多方面的區域策略，以平衡集中式臨床開發與針對特定國家的准入計劃，並與區域關鍵意見領袖合作，從而支持指南的採納和檢測規模的擴大。

在所有地區，產業界、臨床學會和支付方之間的合作，旨在擴大檢測範圍並將PARP抑制劑納入標準化治療方案，這將影響PARP抑制劑的普及率。跨境臨床試驗網路和資料共用計畫也有助於完善依證，從而更全面地了解其安全性和長期療效。認知並解決監管時間、診斷可及性和支付方優先事項的區域差異，對於有效的全球計畫規劃和確保患者公平獲得PARP定向治療至關重要。

關鍵的公司策略洞察揭示了臨床開發聯盟、診斷夥伴關係和商業模式如何使各公司在PARP抑制劑專案方面採取不同的策略。

對活躍於PARP抑制劑領域的主要企業進行的一項專案調查顯示，各公司在研發重點、臨床證據產生和商業性定位方面存在策略差異。有些公司專注於以生物標記為導向的適應症拓展和聯合治療，而有些公司則強調差異化的安全性和患者支持體系，以確保患者堅持口服治療方案。策略聯盟和聯合開發夥伴關係十分普遍，各公司尋求互補的專業知識，以追求協同效應並分散臨床風險，例如將PARP抑制劑與免疫腫瘤療法或血管生成抑制劑聯合使用。

製造商也在投資診斷夥伴關係，以便在早期階段可靠地識別合格的人群，上游工程。那些採取垂直整合策略，將診斷能力與治療相結合的公司，能夠更好地減少患者就醫過程中的摩擦。競爭格局將取決於能否證明其數據在不同適應症中的可靠性，以及能否提出能夠引起支付方和醫療服務提供者共鳴的清晰價值提案。

商業策略涵蓋了從注重依從性支援的集中式專科藥房模式到以數位化病人參與工具為支撐的廣泛零售。整個產業越來越關注人群定序策略，該策略會考慮領先治療、潛在的交叉抗藥性和老年族群的耐受性。這些策略轉變凸顯了臨床開發、診斷、商業營運和支付方合作的必要性，以將臨床療效轉化為永續的患者用藥途徑。

為產業領導者提供切實可行的建議，以整合生物標記策略，加強PARP抑制劑計畫的真實世界證據供應鏈韌性和支付方參與度。

產業領導者應優先採取以下幾項切實可行的措施，以提升PARP抑制劑在臨床、商業和營運方面的績效。首先，從早期研發到商業化，整合一套全面的生物標記策略至關重要。這包括支持診斷規模化、確保及時獲得檢測報銷，以及投資臨床醫生教育，以縮短從診斷到治療的延誤時間。這樣做將有助於企業識別合適的患者，並提高治療部署的效率。

其次，申辦方應開展強力的真實世界證據項目，以補充臨床試驗，重點關注療效比較、長期安全性以及與健康相關的生活品質。這些數據將為與支付方的談判以及最佳實踐指南的製定提供基礎。第三，申辦者可以透過建立靈活的供應鏈來增強應對能力，從而應對與貿易和關稅相關的潛在中斷。製造地多元化和策略性庫存管理可以降低藥品短缺和價格波動的風險。

第四，商業團隊應透過建構差異化的價值敘事來解決支付方的顧慮，強調可衡量的結果、減少後續資源消耗以及患者報告的獲益，而不是僅依賴價格。第五，考慮為患有併發症的老年患者提供模組化的患者援助計劃，以解決用藥依從性、毒性管理和後勤保障等問題。最後，儘早與醫療監管機構和支付方進行透明溝通，使循證實踐與報銷要求保持一致，並在適當情況下設計基於結果的合約。這些措施將有助於建立更可預測的准入途徑，並加強臨床效益與經濟價值之間的匹配。

一項嚴謹的調查方法，用於分析PARP抑制劑的臨床和商業性動態。

本分析的調查方法結合了多源證據綜合和定性專家意見，以全面了解PARP抑制劑療法。主要研究包括對腫瘤科臨床醫生、醫院藥劑師、專科藥房經理和醫保顧問進行結構化訪談，以了解當地對診斷流程、治療順序和用藥障礙的觀點。此外，還對同行評審的臨床文獻、監管文件和指南聲明進行了系統性回顧，以確認其與目前的臨床標準和安全性數據相符。

次要分析納入了公開的臨床試驗註冊庫、監管公告和真實世界證據出版物，附加檔變更、關鍵臨床試驗結果和核准後研究。為確保解讀準確，我們關注了研究人群和生物標記定義的異質性。分析框架評估了治療方法在不同治療線中的定位、安全性和耐受性權衡以及商業性准入方面的考量，同時情境規劃考慮了供應鏈中斷和支付方預期變化的影響。

品質保證流程包括將訪談結果與已發表的資料進行交叉檢驗，與監管資訊來源的資料進行三角核實，以及進行內部專家審查，以發現任何不一致或缺失之處。調查方法和資料來源的透明度受到重視，優先考慮能夠直接指導臨床決策、與支付方互動以及參與PARP抑制劑開發和商業化相關相關人員營運規劃的證據，尤其是在缺乏直接比較證據的情況下。

總結全文，重點闡述生物標記科學特定證據的生成和整合商業化策略將如何決定PARP抑制劑未來的應用和影響。

總之，PARP抑制劑是一類日益成熟且不斷發展的標靶治療，在生物標記定義的特定族群中具有顯著的臨床療效。基因組診斷的進步、策略性聯合治療試驗的開展以及為解答支付方和醫療服務提供方的疑問而提供強力的真實世界證據，將共同塑造這一藥物的發展軌跡。相關人員必須了解並適應不同地區的監管和報銷政策，適應分銷和治療環境的變化，並預見宏觀經濟和貿易政策變化帶來的供應鏈壓力。

在這種環境下取得成功取決於整合診斷、臨床開發和商業性執行的整合策略。優先透過可靠的檢測途徑識別患者，投資於能夠證明價值而非替代終點的證據，以及設計以患者為中心的支持項目，這些措施將共同提高治療方案的採納率和長期治療依從性。產業、臨床協會、支付方和醫療服務提供者之間的協作可以加速指南的推廣應用，擴大適當的醫療服務覆蓋範圍，同時保持財務永續性。

最終，PARP抑制劑療法的持續發展將取決於生物標記科學的實力、證明有意義的臨床和真實世界結果的能力，以及組織將快速變化的臨床需求與生產、分銷和支付方參與相結合的靈活性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 新一代口服PARP抑制劑的臨床應用，具有更高的安全性和耐受性
  • PARP抑制劑已核准用於BRCA突變以外的適應症，這項里程碑式的監管核准擴大了患者的治療範圍。
  • 策略夥伴關係推進PARP抑制劑抗體藥物複合體的研發，以增強腫瘤標靶化
  • 鑑定新型預測性生物標記物，以最佳化PARP抑制劑的患者選擇和治療結果
  • PARP抑制劑抗藥性機制的出現推動了二線聯合治療策略的創新。
  • 真實世界證據表明，在卵巢癌治療中，維持性使用PARP抑制劑具有長期成本效益並能改善患者的生活品質。
  • 開發一系列長效注射型PARP抑制劑，以提高患者用藥依從性並降低給藥頻率

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. PARP抑制劑治療市場依適應症分類

  • 乳癌
    • 受體類型
      • 荷爾蒙受體陽性
      • 三重否定
  • 卵巢癌
    • 生物標記狀態
      • BRCA基因突變
      • HRD
      • 非人力資源開發
  • 胰臟癌
    • 階段
      • 進步
      • 早期檢測類型
  • 攝護腺癌
    • 階段
      • 轉移性
      • 非轉移性

9. PARP抑制劑治療市場（依藥物分類）

  • 尼拉帕利
  • 奧拉帕尼
  • 魯卡帕尼
  • 他拉唑帕利

10. PARP抑制劑治療市場（依治療領域分類）

  • 主要治療
  • 維持治療
  • 二線治療及後續治療

11. PARP抑制劑治療市場依治療領域分類

  • 住院病人
  • 門診病人

12. PARP抑制劑治療市場（按最終用戶分類）

  • 醫院
  • 零售藥房
  • 專科診所

13. PARP抑制劑治療市場按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

14. PARP抑制劑治療市場依治療類型分類

  • 聯合治療
  • 單藥治療

15. 按患者年齡層分類的 PARP 抑制劑治療市場

  • 成人
  • 老年人

16. PARP抑制劑治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

17. PARP抑制劑治療市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

18. 各國PARP抑制劑治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭情勢

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AstraZeneca plc
    • GlaxoSmithKline plc
    • Clovis Oncology, Inc.
    • Pfizer Inc.
    • Merck & Co., Inc.
Product Code: MRR-AD517FAA716F

The PARP Inhibitors Drug Therapy Market is projected to grow by USD 15.11 billion at a CAGR of 9.47% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.32 billion
Estimated Year [2025] USD 8.01 billion
Forecast Year [2032] USD 15.11 billion
CAGR (%) 9.47%

Comprehensive introduction to PARP inhibitor therapeutics emphasizing clinical rationale regulatory milestones and delivery dynamics shaping adoption across oncology care

The evolution of targeted oncology therapeutics has placed PARP inhibitors at the forefront of precision medicine, with expanding indications and increasing clinical sophistication. This introduction outlines the therapeutic rationale behind PARP inhibition, the current clinical corridors where these agents exert the most impact, and the broader ecosystem of stakeholders shaping their adoption. It situates readers within the therapeutic context without attempting to quantify market size, instead emphasizing mechanisms of action, regulatory landmarks, and clinical endpoints that drive decision-making.

PARP inhibitors exploit tumor-specific vulnerabilities in DNA damage repair pathways, creating synthetic lethality in cancers reliant on homologous recombination deficiencies. Their clinical utility spans several solid tumors with distinct biomarker profiles and disease stages. From initial monotherapy approvals to contemporary combination regimens and maintenance strategies, the PARP class has demonstrated durable responses in selected patient subsets and become a viable option across multiple lines of therapy. This introduction highlights those clinical inflection points and prepares the reader to understand how indication, biomarker status, and therapeutic context influence development and commercialization.

Concurrently, healthcare delivery trends-ranging from outpatient oncology infusion expansion to shifts in specialty pharmacy distribution-are reshaping how PARP inhibitors reach patients. Payer expectations and real-world evidence initiatives increasingly inform treatment algorithms, while clinician practice patterns adapt to evolving guideline recommendations. This section sets the stage for a deeper exploration of transformative shifts, segmentation nuances, regulatory and reimbursement dynamics, and practical recommendations for stakeholders seeking to navigate the complexity of PARP inhibitor deployment across therapeutic settings.

Detailed analysis of the major transformative shifts reshaping PARP inhibitor clinical practice development strategies regulatory pathways and access models

The landscape of PARP inhibitor therapy is undergoing transformative shifts driven by advances in biomarker science, combination therapy development, and evolving regulatory frameworks. Biomarker refinement, particularly around BRCA mutations and broader homologous recombination deficiency signatures, has expanded both the clinical rationale for use and the precision of patient selection. As genomic profiling becomes integrated into earlier lines of clinical decision-making, clinicians are better able to identify candidates for PARP-directed interventions and to sequence therapies around targeted and immuno-oncology agents.

Simultaneously, the therapeutic paradigm is moving from single-agent maintenance strategies to more complex combination regimens that pair PARP inhibitors with anti-angiogenics, immune checkpoint inhibitors, or cytotoxic agents. These combinations aim to broaden the responsive patient population and enhance depth of response, but they also introduce new considerations in safety management, dosing optimization, and payer negotiation. Regulatory pathways have adapted to these developments with label expansions tied to biomarker-defined populations and accelerated approvals that require robust confirmatory evidence; this regulatory dynamism influences clinical trial design and commercial planning alike.

Delivery models are shifting as well. The rise of outpatient and specialty clinic administration, coupled with expanded roles for retail and online pharmacy distribution channels, affects patient access and adherence. Real-world evidence programs and post-approval studies are increasing in importance as stakeholders seek to validate long-term outcomes, comparative effectiveness, and value propositions. Taken together, these shifts are redefining clinical pathways and commercial strategies, requiring agile cross-functional teams to align clinical development, regulatory engagement, and payer communication in order to maximize therapeutic impact.

Examination of how cumulative United States tariffs implemented through 2025 influenced pharmaceutical supply chains commercial strategies access considerations and payer engagement

The imposition of cumulative tariffs in the United States through 2025 introduced a range of cost headwinds for pharmaceutical supply chains, with implications for procurement, pricing strategies, and stakeholder negotiations. These tariff measures affected active pharmaceutical ingredient sourcing, finished product imports, and ancillary medical supplies, prompting many manufacturers and distributors to reassess supplier diversification, inventory management, and contractual terms with global partners. Companies with concentrated manufacturing footprints outside the U.S. faced discrete pressures to adapt logistics and mitigate cost pass-through to payers and providers.

In response, many stakeholders prioritized supply chain resiliency by identifying alternate manufacturing sites, nearshoring critical components, and renegotiating vendor contracts to secure longer-term price certainty. Payers and integrated delivery networks increased scrutiny on unit costs and therapy affordability, accelerating adoption of value-based contracting approaches and outcomes-based reimbursement pilots. At the provider level, institutions revisited formulary placement and chemotherapy pathway protocols to preserve therapeutic continuity while managing budgetary constraints.

Clinically, the tariff-driven environment reinforced the importance of demonstrating differential value across PARP agents, particularly where therapeutic interchangeability is debated. Real-world evidence collection and pharmacoeconomic modeling became more central to payer discussions, shaping coverage and prior authorization workflows. These collective adjustments underscore how macroeconomic and trade policies can exert downstream pressure on innovation adoption, necessitating proactive supply chain strategies, rigorous value demonstration, and collaborative engagement with payers and providers to sustain patient access during periods of external cost volatility.

In-depth segmentation insights that connect indication biomarker profiles drug characteristics lines of therapy treatment settings and distribution channels to clinical and commercial strategies

Robust segmentation is essential to understand the heterogeneous patient populations and clinical contexts in which PARP inhibitors operate, beginning with indication-level distinctions. In breast cancer, stratification by receptor type separates hormone receptor-positive disease from triple-negative disease, each with distinct responsiveness patterns and therapeutic sequencing implications. Ovarian cancer requires granular attention to biomarker status, with BRCA-mutated, homologous recombination deficiency-positive, and non-HRD cohorts showing varied sensitivity to PARP-directed approaches. Pancreatic cancer segmentation by stage distinguishes patients with advanced disease from those in earlier stages, which influences the feasibility of maintenance strategies and trial eligibility. Prostate cancer similarly pivots on stage differentiation, separating metastatic from non-metastatic disease and altering endpoints, survival expectations, and integration with androgen receptor-targeted therapies.

Drug-level differentiation among Niraparib, Olaparib, Rucaparib, and Talazoparib drives clinical positioning based on pharmacologic profiles, dosing schedules, safety signals, and approved or investigational indications. Line-of-therapy segmentation-first line, maintenance, and subsequent lines-affects objectives of treatment, whether induction of response, prolongation of progression-free intervals, or salvage therapy after resistance. Treatment setting is another critical axis: inpatient versus outpatient contexts shape administration logistics, monitoring resources, and the role of infusion centers versus oral therapy management in ambulatory oncology practices.

End users such as hospitals, retail pharmacies, and specialty clinics interact with distribution channels including hospital pharmacies, online pharmacies, and retail pharmacy networks, creating diverse access pathways and adherence touchpoints. Therapy type divides into combination therapy and monotherapy considerations, which impact safety management and payer negotiations. Finally, patient age group segmentation into adults and elderly introduces differences in comorbidity burden, polypharmacy risks, and real-world tolerability that must inform clinical protocols and patient support programs. Integrating these layered segmentation lenses supports more precise clinical trial cohorts, sharper value narratives for payers, and tailored patient support models that enhance adherence and outcomes.

Key regional insights highlighting how Americas Europe Middle East Africa and Asia-Pacific differences in regulation diagnostics and payer priorities shape PARP inhibitor adoption

Regional dynamics shape how PARP inhibitors are developed, approved, and adopted, with each geography presenting distinct clinical practices, regulatory expectations, and payer landscapes. In the Americas, regulatory authorities and payers emphasize comparative effectiveness and real-world performance, while clinical adoption is influenced by established genomic testing pathways and a high prevalence of integrated specialty pharmacy services. These factors create an environment where differentiated clinical evidence and payer-centric value demonstration are particularly influential in shaping treatment access.

Across Europe, the Middle East, and Africa, heterogeneity in regulatory frameworks and reimbursement systems requires localized evidence generation and nuanced health technology assessment engagement. Variability in genomic testing infrastructure and resource allocation means that uptake can differ substantially even within contiguous markets, driving the need for tailored access strategies, local investigator partnerships, and adaptive pricing approaches that reflect country-level health priorities. In contrast, the Asia-Pacific region presents a mix of rapidly modernizing markets with growing genomic diagnostics capacity and jurisdictions where infrastructure constraints limit the speed of adoption. This diversity necessitates a multifaceted regional strategy that balances centralized clinical development with country-specific access planning and engagement with regional key opinion leaders to support guideline inclusion and testing scale-up.

Across all regions, collaborations between industry, clinical societies, and payers to expand testing access and to integrate PARP inhibitors into standardized treatment pathways influence uptake. Cross-border clinical trial networks and data-sharing initiatives also contribute to the evidence base, enabling broader understanding of safety profiles and long-term outcomes. Recognizing and addressing regional differences in regulatory timing, diagnostic availability, and payer priorities is crucial for effective global program planning and for ensuring equitable patient access to PARP-directed therapies.

Key corporate strategic insights revealing how clinical development alliances diagnostic partnerships and commercial models differentiate company approaches to PARP inhibitor programs

A focused review of key companies active in the PARP inhibitor space reveals strategic diversity in development priorities, clinical evidence generation, and commercial positioning. Some organizations have concentrated on broadening label indications by pursuing biomarker-driven expansions and combination studies, while others emphasize safety differentiation and patient support infrastructures to maintain adherence in oral regimens. Strategic alliances and co-development partnerships have been common as firms seek complementary expertise-such as combining PARP inhibitors with immuno-oncology programs or angiogenesis inhibitors-to pursue synergistic effects and to diversify clinical risk.

Manufacturers are also investing in diagnostics partnerships to ensure upstream identification of eligible populations, recognizing that timely genomic testing is foundational to uptake. Companies with vertically integrated approaches, linking diagnostic capabilities with therapeutic offerings, are better positioned to reduce friction in the patient pathway. Competitive dynamics hinge on demonstrating robustness of data across different indications and on articulating clear value propositions that resonate with payers and providers; head-to-head evidence remains limited, so indirect comparisons and real-world analyses are increasingly used to support positioning.

Commercial strategies vary from centralized specialty pharmacy models that emphasize adherence support to broader retail distribution supported by digital patient engagement tools. Across the industry, there is a growing focus on sequencing strategies that consider prior treatments, potential cross-resistance, and tolerability profiles in older populations. These strategic variations underscore that successful execution requires alignment across clinical development, diagnostics, commercial operations, and payer engagement to translate clinical promise into sustainable patient access.

Actionable recommendations for industry leaders to integrate biomarker strategies enhance real-world evidence supply chain resilience and payer engagement for PARP inhibitor programs

Industry leaders should prioritize several actionable steps to strengthen clinical, commercial, and operational performance around PARP inhibitors. First, integrating comprehensive biomarker strategies from early development through commercialization is essential; this includes supporting diagnostic scale-up, ensuring timely test reimbursement, and investing in clinician education to reduce diagnostic-to-treatment delays. By doing so, organizations can increase identification of appropriate patients and improve the efficiency of therapeutic deployment.

Second, sponsors should pursue robust real-world evidence programs that complement clinical trials, focusing on comparative effectiveness, long-term safety, and health-related quality of life. These data will be instrumental in payer negotiations and in informing best-practice guidelines. Third, building flexible supply chains that accommodate potential trade and tariff-related disruptions enhances resilience; diversification of manufacturing sites and strategic inventory management reduce the risk of therapy shortages and price volatility.

Fourth, commercial teams must craft differentiated value narratives that address payer concerns without relying solely on list-price arguments, emphasizing measurable outcomes, reduction in downstream resource utilization, and patient-reported benefits. Fifth, consider modular patient support programs that address adherence, toxicity management, and logistics for elderly populations with comorbidities. Finally, engage early and transparently with health authorities and payers to align evidence generation with reimbursement requirements, and to design outcomes-based agreements where appropriate. Collectively, these actions foster more predictable access pathways and stronger alignment between clinical benefits and economic value.

Rigorous research methodology detailing primary and secondary evidence synthesis expert interviews and quality assurance measures used to analyze PARP inhibitor clinical and commercial dynamics

The research methodology underpinning this analysis combined a multi-source evidence synthesis with qualitative expert input to produce a comprehensive perspective on PARP inhibitor therapeutics. Primary research included structured interviews with oncology clinicians, hospital pharmacists, specialty pharmacy managers, and payer advisors to capture frontline perspectives on diagnostic workflows, treatment sequencing, and access barriers. These insights were complemented by systematic reviews of peer-reviewed clinical literature, regulatory documents, and guideline statements to ensure alignment with current clinical standards and safety data.

Secondary analysis incorporated publicly available clinical trial registries, regulatory announcements, and real-world evidence publications to track label changes, key trial outcomes, and post-approval studies. Attention was paid to heterogeneity in study populations and biomarker definitions to ensure accurate interpretation. Analytical frameworks assessed therapy positioning across lines of care, safety and tolerability trade-offs, and commercial access considerations, while scenario planning explored implications of supply chain disruptions and evolving payer expectations.

Quality assurance processes included cross-validation of interview findings against published data, triangulation of regulatory sources, and internal expert review to surface any inconsistencies or gaps. The methodology emphasized transparency about data sources and limitations, particularly where head-to-head comparative evidence remains limited, and prioritized evidence that directly informs clinical decision-making, payer dialogues, and operational planning for stakeholders involved in PARP inhibitor development and commercialization.

Conclusive synthesis highlighting how biomarker science evidence generation and integrated commercialization strategies will determine the future adoption and impact of PARP inhibitors

In conclusion, PARP inhibitors represent a mature yet evolving class of targeted oncology therapies with meaningful clinical impact in biomarker-defined populations. The trajectory of the class is shaped by advances in genomic diagnostics, strategic combination trials, and the need for compelling real-world evidence to address payer and provider questions. Stakeholders must navigate region-specific regulatory and reimbursement landscapes, adapt to shifts in distribution and treatment settings, and anticipate supply chain pressures that may arise from macroeconomic and trade policy changes.

Success in this environment depends on integrated strategies that connect diagnostics, clinical development, and commercial execution. Prioritizing patient identification through reliable testing pathways, investing in evidence that demonstrates value beyond surrogate endpoints, and designing patient-centric support programs will collectively enhance adoption and long-term treatment continuity. Collaborative approaches involving industry, clinical societies, payers, and healthcare providers can accelerate guideline incorporation and broaden appropriate access while maintaining fiscal sustainability.

Ultimately, the continued evolution of PARP inhibitor therapy will be determined by the strength of biomarker science, the ability to demonstrate meaningful clinical and real-world outcomes, and the agility of organizations to align manufacturing, distribution, and payer engagement with rapidly changing clinical needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Clinical uptake of next generation oral PARP inhibitors with improved safety and tolerability profiles
  • 5.2. Breakthrough regulatory approvals of PARP inhibitors for non-BRCA mutant indications expanding patient access
  • 5.3. Strategic partnerships driving development of PARP inhibitor antibody drug conjugates for enhanced tumor targeting
  • 5.4. Identification of novel predictive biomarkers to optimize PARP inhibitor patient selection and therapeutic outcomes
  • 5.5. Emerging mechanisms of resistance to PARP inhibitors spurring innovation in second line combination strategies
  • 5.6. Real world evidence highlighting long term cost effectiveness and quality of life benefits of maintenance PARP inhibitor use in ovarian cancer
  • 5.7. Pipeline development of long acting injectable PARP inhibitors aimed at improving adherence and reducing dosing frequency

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. PARP Inhibitors Drug Therapy Market, by Indication

  • 8.1. Breast Cancer
    • 8.1.1. Receptor Type
      • 8.1.1.1. Hormone Receptor Positive
      • 8.1.1.2. Triple Negative
  • 8.2. Ovarian Cancer
    • 8.2.1. Biomarker Status
      • 8.2.1.1. Brca Mutated
      • 8.2.1.2. Hrd
      • 8.2.1.3. Non-Hrd
  • 8.3. Pancreatic Cancer
    • 8.3.1. Stage
      • 8.3.1.1. Advanced
      • 8.3.1.2. Early Stage
  • 8.4. Prostate Cancer
    • 8.4.1. Stage
      • 8.4.1.1. Metastatic
      • 8.4.1.2. Non-Metastatic

9. PARP Inhibitors Drug Therapy Market, by Drug

  • 9.1. Niraparib
  • 9.2. Olaparib
  • 9.3. Rucaparib
  • 9.4. Talazoparib

10. PARP Inhibitors Drug Therapy Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Maintenance
  • 10.3. Subsequent Line

11. PARP Inhibitors Drug Therapy Market, by Treatment Setting

  • 11.1. Inpatient
  • 11.2. Outpatient

12. PARP Inhibitors Drug Therapy Market, by End User

  • 12.1. Hospitals
  • 12.2. Retail Pharmacies
  • 12.3. Specialty Clinics

13. PARP Inhibitors Drug Therapy Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. PARP Inhibitors Drug Therapy Market, by Therapy Type

  • 14.1. Combination Therapy
  • 14.2. Monotherapy

15. PARP Inhibitors Drug Therapy Market, by Patient Age Group

  • 15.1. Adults
  • 15.2. Elderly

16. PARP Inhibitors Drug Therapy Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. PARP Inhibitors Drug Therapy Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. PARP Inhibitors Drug Therapy Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. AstraZeneca plc
    • 19.3.2. GlaxoSmithKline plc
    • 19.3.3. Clovis Oncology, Inc.
    • 19.3.4. Pfizer Inc.
    • 19.3.5. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PARP INHIBITORS DRUG THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BRCA MUTATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BRCA MUTATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BRCA MUTATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BRCA MUTATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BRCA MUTATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BRCA MUTATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HRD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HRD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HRD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HRD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HRD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HRD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-HRD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-HRD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-HRD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-HRD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-HRD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-HRD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADVANCED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADVANCED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADVANCED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADVANCED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADVANCED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADVANCED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY EARLY STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY METASTATIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY METASTATIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY METASTATIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY METASTATIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY METASTATIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY METASTATIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-METASTATIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-METASTATIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-METASTATIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-METASTATIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-METASTATIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-METASTATIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2024 (USD MILLION)

TABLE 30